期刊文献+

基于关联规则Apriori算法的真实世界复方苦参注射液治疗恶性肿瘤联合用药药理作用特征的回顾分析 被引量:39

Association rules analysis of Fufang Kushen injection in combination with traditional Chinese medicine or modern medications in treating malignant tumor: real-world retrospective study
原文传递
导出
摘要 探索真实世界复方苦参注射液联合用药特征,针对其治疗恶性肿瘤的临床联用中西药物药理作用关联规律进行分析,为临床合理用药、治法模式的探索及后续深入分析提供参考借鉴。对来自22家医院诊断为恶性肿瘤且使用复方苦参注射液治疗的44 588例患者电子医疗数据进行提取,基于关联规则Apriori算法对所记载的联用中西药物药理特征进行基于电子医疗数据的真实世界回顾分析。研究结果解析了复方苦参注射液与中西药物联合应用治疗恶性肿瘤的真实世界临床规律,为临床治疗思路的拓展提供了有益参考,并为复方苦参注射液的临床合理应用提供了借鉴。鉴于该研究结果不具有强关联性及因果关系推断性,相关结论有待进一步深入研究分析验证。 Fufang Kushen injection is used in real world clinical situations to treat different types of malignant tumors. The present study aimed to analyze the association rules of Fufang Kushen injection in combination with other traditional Chinese medicine( TCM)or modern medications in treating malignant tumors based on the electrical medical records extracted from real-world hospital information system. This real world retrospective analysis was based on the clinicians ’ prescriptions regarding to such treatment by combined TCM and modern medications. Hospital information system data from 22 hospitals,including electrical medical records of 44 588 patients with malignant tumors and Fufang Kushen injection were included in this study,providing useful reference for the development of clinical treatment ideas,and providing reference for clinical rational use of Fufang Kushen injection. High correlation and causal relations were not present in this study,so further exploration and analysis were still needed for the conclusion.
出处 《中国中药杂志》 CAS CSCD 北大核心 2017年第2期378-384,共7页 China Journal of Chinese Materia Medica
基金 国家"重大新药创制"科技重大专项(2015ZX09501004-001-002) 北京市中医药科技发展专项(JJ2014-53) 中国中医科学院自主选题项目(PY1303)
关键词 复方苦参注射液 真实世界 恶性肿瘤 联合用药 关联规则 Fufang Kushen injection real world malignant tumor drug combinations association rules
  • 相关文献

参考文献2

二级参考文献19

  • 1Aikawa N, Ishizaka A, Hirasawa H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study[ J]. Pulm Pharmacol Ther,2011 ,doil0. 1016/j. pupt. 2011.03. 001.
  • 2Liang B A. FDA use of the black box warning: time for re-evaluation as a safety tool[ J ]. J Clin Anesth ,2002,14 ( 8 ) :598.
  • 3Paul R Rosenbaum, Donald B Rubin. The central role of the propensity score in observational studies for causal effects [ J ]. Biometrika,1983, 1 (70) : 41.
  • 4Inrbens G W, Angrist J D. Indentification and estimation of local average treatment effect[ J]. Econometrica, 1994, 62 : 467.
  • 5D'Agostino R B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group[ J]. Stat Med, 1998,17:2265.
  • 6Rubin D B. Matching using estimated propensity scores: relating theory to practice[ J]. Biometrics, 1996, 52:249.
  • 7Paul R, Rubin D B. Reducing bias in observational studies using subclassification on the propensity score [ J ]. J Am Star Assoc, 1984,79:516.
  • 8Robins J M, Hernan M A, B rumback B. Marginal structural models and causal inference in epidemiology [ J ]. Epidemiology, 2000, 11:550.
  • 9Heman M A, Brumback B, Robins J M. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men [ J ]. Epidemiology, 2000, 11 : 561.
  • 10Sato T, Matsuyama Y. Marginal structural models as a tool for standardization[J]. Epidemiology, 2003, 14: 680.

共引文献179

同被引文献662

引证文献39

二级引证文献278

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部